ABBVIE
A Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
- Conditions
- Interventions
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2016-11-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 222
- Registration Number
- NCT02141997
A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy
- First Posted Date
- 2014-05-19
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 127
- Registration Number
- NCT02141282
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center /ID# 134509, Boston, Massachusetts, United States
🇺🇸University of Utah /ID# 130813, Salt Lake City, Utah, United States
🇺🇸Moores Cancer Center at UC San Diego /ID# 128535, La Jolla, California, United States
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
- Conditions
- First Posted Date
- 2014-05-05
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1446
- Registration Number
- NCT02130362
- Locations
- 🇺🇸
Massachusetts General Hospital /ID# 141552, Boston, Massachusetts, United States
🇺🇸Rady Children's Hospital San Diego /ID# 140883, San Diego, California, United States
🇬🇷General Hospital of Thessaloniki Gennimatas /Id# 163658, Thessaloniki, Greece
Atrasentan Spermatogenesis and Testicular Function
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 20
- Registration Number
- NCT02118714
- Locations
- 🇺🇸
Tulane Univ /ID# 130308, New Orleans, Louisiana, United States
🇺🇸Frank Clark Urology Center /ID# 147794, Santa Monica, California, United States
🇺🇸Southern IL Univ School of Med /ID# 129010, Springfield, Illinois, United States
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 970
- Registration Number
- NCT02106546
- Locations
- 🇺🇸
Winship Cancer Institute of Emory University /ID# 124061, Atlanta, Georgia, United States
🇺🇸Parkland Health and Hosp Syste /ID# 128518, Dallas, Texas, United States
🇺🇸Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 128385, Dallas, Texas, United States
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2014-03-28
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 237
- Registration Number
- NCT02099058
- Locations
- 🇺🇸
University of California, Los Angeles /ID# 148295, Los Angeles, California, United States
🇺🇸Massachusetts General Hospital /ID# 129804, Boston, Massachusetts, United States
🇺🇸Duke Cancer Center /ID# 123763, Durham, North Carolina, United States
A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- AbbVie
- Registration Number
- NCT02095574
Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo
- Conditions
- First Posted Date
- 2014-03-20
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 10
- Registration Number
- NCT02092389
A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis
- Conditions
- Interventions
- First Posted Date
- 2014-03-14
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 350
- Registration Number
- NCT02087904
A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell Lymphoma
- Conditions
- First Posted Date
- 2014-03-14
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- AbbVie
- Registration Number
- NCT02087878
- Locations
- 🇮🇹
AOU Pisana /ID# 208952, Pisa, Italy